Deciphering Cancer Resistance: Mechanisms, Targets, and Emerging Therapies addresses the critical challenge of treatment resistance in oncology. The book provides a comprehensive examination of the cellular, molecular, and genetic mechanisms behind resistance, unveiling insights from cancer biology and genomics that inform novel therapeutic strategies. Sections explore cutting-edge technologies like CAR-T cell therapy, nanotechnology, and artificial intelligence, highlighting their role in discovering new treatment modalities. Readers will find the latest preclinical and clinical data, including newly FDA-approved therapies, demonstrating their potential to improve patient outcomes.
For academics, this resource consolidates the latest research and clinical developments, aiding researchers, clinicians, and students in staying updated on advancements. It will also be a great guide for graduate studies and research, offering critical insights into drug development and targeted therapies for professionals in the pharmaceutical and biotechnology sectors, ultimately driving progress in cancer treatment.
For academics, this resource consolidates the latest research and clinical developments, aiding researchers, clinicians, and students in staying updated on advancements. It will also be a great guide for graduate studies and research, offering critical insights into drug development and targeted therapies for professionals in the pharmaceutical and biotechnology sectors, ultimately driving progress in cancer treatment.
Table of Contents
Part I: Molecular and Cellular Mechanisms Underlying Cancer Resistance (Chapters 1-5)1. Molecular Pathways in Cancer Resistance: A Comprehensive Overview
2. Role of Tumor Microenvironment in Therapy Resistance
3. Epigenetic Modifications and Drug Resistance in Cancer
4. Cancer Stem Cells as Drivers of Resistance to Conventional Therapies
5. Mechanisms of Immune Escape and Resistance to Immunotherapy in Cancer Treatment
Part II: Emerging Therapeutic Approaches to Overcome Resistance (Chapters 6-13)
6. Targeting Epigenetic Regulators: Promising Avenues
7. CRISPR and Gene Editing in Combating Drug Resistance
8. Synthetic Lethality and PARP Inhibitors in Resistant Tumors
9. Role of Nanomedicine in Delivering Targeted Therapies
10. Overcoming Resistance to Immunotherapy with Checkpoint Blockade
11. Exploiting Tumor Metabolism to Reverse Resistance
12. The Role of MicroRNAs and Non-coding RNAs in Therapeutic Resistance
13. Overcoming Cancer Resistance: The Role of Emerging CAR-T Cell Approaches
Part III: Clinical Applications and Future Perspectives (Chapters 14-18)
14. Biomarker Development for Predicting Therapy Resistance
15. Precision Medicine in the Context of Cancer Resistance
16. Combination Therapies to Enhance Treatment Efficacy in Resistant Cancers
17. AI-Driven Approaches to Overcoming Cancer Resistance
18. Future Directions in Overcoming Cancer Resistance: Challenges and Opportunities
Authors
Abraham Pedroza Hereditary Cancer Clinic, Mexico. Dr. Pedroza is a specialist in molecular biology and cancer research, with a focus on identifying molecular markers associated with treatment resistance in ovarian cancer. His research also explores the role of cellular exosomes in modulating the tumor microenvironment and influencing the response to cisplatin therapy. Rosa M. Alvarez-Gomez National Cancer Institute, Mexico.Dr. Alvarez-Gomez is aspecialist in genetics and cancer risk assessment. Currently, she is the chief of the Hereditary Cancer Clinic at National Cancer Institute (INCAN), Mexico. Dr. Alvarez's multidisciplinary clinical and research program emphasizes the relevance of the translational medicine in diagnosis, treatment and assessment of patients with inherited cancer and their families.
